New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareEpithalon vs Orforglipron

Epithalon vs Orforglipron

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Epithalon
GLP-1 / Weight Loss Agonists
Orforglipron
Summary
Epithalon is a synthetic tetrapeptide developed from the pineal gland extract Epithalamin by Russian scientist Dr. Vladimir Khavinson. It is one of the most researched longevity peptides, known for activating telomerase and extending telomere length — the molecular hallmarks of cellular aging.
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
Half-Life
2–4 hours
~12 hours (once-daily oral dosing)
Admin Route
SubQ, Sublingual
Oral
Research
Typical Dose
5–10 mg total per cycle
12 mg → 24 mg → 36 mg → 45 mg
Frequency
0.5–1 mg daily
Once daily
Key Benefits
  • Activates telomerase enzyme, extending telomere length
  • May slow cellular and biological aging
  • Regulates melatonin production and circadian rhythms
  • Improves sleep quality
  • Powerful antioxidant properties
  • May reduce incidence of age-related diseases
  • Supports immune system function
  • Studied for cancer prevention properties in animal models
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
Side Effects
  • Injection site irritation (mild)
  • Temporary sleep changes during cycle (usually improves)
  • Rare: fatigue
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
Stacks With